brivumen tablett
berlin-chemie ag - brivudiin - tablett - 125mg 7tk; 125mg 1tk; 125mg 35tk
amantadin-ratiopharm 100 mg õhukese polümeerikattega tablett
ratiopharm gmbh - amantadiin - õhukese polümeerikattega tablett - 100mg 50tk; 100mg 100tk
zemertinex suus dispergeeruv tablett
pharmaswiss ceska republika s.r.o. - memantiin - suus dispergeeruv tablett - 15mg 98tk; 15mg 28tk; 15mg 30tk
memantine alvogen suus dispergeeruv tablett
alvogen ipco s.a.r.l. - memantiin - suus dispergeeruv tablett - 5mg/10mg/15mg/20mg 5mg 7tk / 10mg 7tk / 15mg 7tk / 20mg 7tk
memantine alvogen suus dispergeeruv tablett
alvogen ipco s.a.r.l. - memantiin - suus dispergeeruv tablett - 20mg 28tk; 20mg 56tk
memantine alvogen suus dispergeeruv tablett
alvogen ipco s.a.r.l. - memantiin - suus dispergeeruv tablett - 10mg 56tk
celsunax
pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostilised radiofarmatseutilised ühendid - see ravim on mõeldud ainult diagnostiliseks kasutamiseks. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. täiskasvanud patsientidel, et aidata eristada arvatav dementsus koos lewy kehad alzheimeri tõbi. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.
lercapin õhukese polümeerikattega tablett
ideal trade links uab - lerkanidipiin - õhukese polümeerikattega tablett - 10mg 35tk; 10mg 56tk; 10mg 90tk; 10mg 28tk; 10mg 100tk; 10mg 60tk; 10mg 7tk; 10mg 50tk